Evidence map›Paper›PMID 22282663›Full record

ArticleCancer research2012

Ovarian cancer risk associated with inherited inflammation-related variants.

Kristin L White, Joellen M Schildkraut, Rachel T Palmieri, Edwin S Iversen, Andrew Berchuck, Robert A Vierkant, David N Rider, Bridget Charbonneau, Mine S Cicek, Rebecca Sutphen and 15 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Targeted immune therapy of ovarian cancer.Cancer metastasis reviews · 2015
    Review
  18. Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 2 countries.

Kristin L WhiteMayo Clinic College of Medicine, Rochester, MN 55905, USA.
Joellen M Schildkraut
Rachel T Palmieri
Edwin S Iversen
Andrew Berchuck
Robert A Vierkant
David N Rider
Bridget Charbonneau
Mine S Cicek
Rebecca Sutphen
Michael J Birrer
Paul P D Pharoah
Honglin Song
Jonathan Tyrer
Simon A Gayther
Susan J Ramus
Nicolas Wentzensen
Hannah P Yang
Montserrat Garcia-Closas
Catherine M Phelan
Julie M Cunningham
Brooke L Fridley
Thomas A Sellers
Ellen L Goode
Ovarian Cancer Association Consortium
Duke University · USUniversity of Cambridge · GBMoffitt Cancer Center · USNational Cancer Institute · USFlorida College · US

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Haplotype-Based Genome Screen for Ovarian Cancer LociR01CA114343 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2007 to 2011
$7.5M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
Mayo Cancer Genetic Epidemiology Training ProgramR25CA092049 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M., VACHON, CELINE M · 2001 to 2018
$5.3M
The Mitochondrial Genome and Ovarian Cancer RiskR01CA149429 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PHELAN, CATHERINE · 2010 to 2015
$3.1M
Population-Based Analysis of Ovarian Cancer BiomarkersR01CA106414 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SUTPHEN, REBECCA · 2005 to 2009
$3.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Estrogen Bioactivation and Risk of Ovarian CancerR01CA086888 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI SELLERS, THOMAS A · 2002 to 2005
$2.0M
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK A10119Cancer Research UK A10124Cancer Research UK A11306Cancer Research UK A6187Cancer Research UK A7058Cancer Research UK A8339Medical Research Council G0801875Medical Research Council G0801875(89310)Medical Research Council G0801875-89310NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA086888NCI NIH HHS R01-CA086888NCI NIH HHS R01 CA106414NCI NIH HHS R01-CA106414NCI NIH HHS R01 CA114343NCI NIH HHS R01-CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01-CA122443NCI NIH HHS R01 CA149429NCI NIH HHS R01-CA76016NCI NIH HHS R25 CA092049NCI NIH HHS U19 CA148112NCI NIH HHS U19-CA148112
6 · The paper itself

Abstract

The importance of inflammation pathways to the development of many human cancers prompted us to examine the associations between single-nucleotide polymorphisms (SNP) in inflammation-related genes and risk of ovarian cancer. In a multisite case-control study, we genotyped SNPs in a large panel of inflammatory genes in 930 epithelial ovarian cancer cases and 1,037 controls using a custom array and analyzed by logistic regression. SNPs with P < 0.10 were evaluated among 3,143 cases and 2,102 controls from the Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) post-GWAS collaboration. Combined analysis revealed association with SNPs rs17561 and rs4848300 in the interleukin gene IL1A which varied by histologic subtype (P(heterogeneity) = 0.03). For example, IL1A rs17561, which correlates with numerous inflammatory phenotypes, was associated with decreased risk of clear cell, mucinous, and endometrioid subtype, but not with the most common serous subtype. Genotype at rs1864414 in the arachidonate 5-lipoxygenase ALOX5 was also associated with decreased risk. Thus, inherited variation in IL1A and ALOX5 seems to affect ovarian cancer risk which, for IL1A, is limited to rarer subtypes. Given the importance of inflammation in tumorigenesis and growing evidence of subtype-specific features in ovarian cancer, functional investigations will be important to help clarify the importance of inherited variation related to inflammation in ovarian carcinogenesis.

Indexed as

Polymorphism, Single Nucleotide5-Lipoxygenase-Activating ProteinsCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansInflammationInterleukin-1alphaNeoplasms, Glandular and EpithelialOvarian NeoplasmsRisk5-Lipoxygenase-Activating ProteinsALOX5AP protein, humanIL1A protein, humanInterleukin-1alpha

Identifiers

PMID22282663
PMCPMC3293997
OpenAlexW2089755408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.